The use of sodium sulfacetamide 10%-sulfur 5% emollient foam in the treatment of acne vulgaris

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 8, 2009, Pages 26-29

  Del Rosso, James Q ^a  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTI ACNE AGENT; BENZOYL PEROXIDE; CLINDAMYCIN; DOXYCYCLINE; EMOLLIENT AGENT; MINOCYCLINE; RETINOIC ACID; SULFACETAMIDE; TAZAROTENE;

ACNE VULGARIS; ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CHEEK; CHIN; COMEDO; DRY SKIN; EVENING DOSAGE; FEMALE; FOREHEAD; HUMAN; HYPERPIGMENTATION; MALE; MONOTHERAPY; MORNING DOSAGE; PAPULE; PATIENT SATISFACTION; PRURITUS; SKIN REDNESS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77954285158     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Centers for Disease Control and Prevention, National Center for Health Statistics, 2005 National Ambulatory Medical Care Survey, March 2005.
2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49 (Suppl):S1-S37.
3. Gupta AK, Nicol K. The use of sulfur in dermatology. J Drugs Dermatol. 2004;3:427-431.
4. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73 (Suppl 1):29-33.
5. Clarifoam-EF Emollient Foam [package insert]. Cumberland, RI: Onset Therapeutics; 2008.
6. Trumbore M. The moisturization ability of a sodium sulfacetamide (10%)/sulfur (5%) emollient foam. J Am Acad Dermatol. 2007;56:AB21 (Abstract P134).
7. Trumbore MW, Macey JM, Schilling W. The rate of release of active ingredients from a novel wash-off and leave-on sodium sulfacetamide 10%/sulfur 5% emollient foam. Poster presented at: 66th Annual Meeting of the American Academy of Dermatology; February 1-5, 2008; San Antonio, TX.
8. Trumbore MW. The development of an in-vitro assay for determining the antimicrobial efficacy of leave-on and wash-off topical acne medications. Poster presented at: American Academy of Dermatology Summer Academy Meeting; August 1-5, 2007; New York, NY.
9. Gurge R, Trumbore MW, Varanasi R. The evaluation of a novel pharmaceutical foam vehicle technology optimized to improve patient compliance. Poster presented at: American Academy of Dermatology Summer Academy Meeting; July 30-August 3, 2008; Chicago, IL.
10. Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quant-itative assessment of vehicle preference. Cutis. 2002;70: 327-332.